Home / Health / Weight-Loss Jabs Linked to Severe Pancreatitis Risk
Weight-Loss Jabs Linked to Severe Pancreatitis Risk
30 Jan
Summary
- UK regulators updated guidance due to increased pancreatitis reports.
- Over 1.6 million adults used GLP-1 weight-loss jabs in England, Wales, Scotland.
- MHRA identified 1,143 pancreatitis reports, including 17 fatalities.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has updated its guidance concerning GLP-1 weight-loss medications, such as semaglutide and tirzepatide. This action follows an observed rise in reports of severe acute pancreatitis associated with these drugs.
Between early 2024 and early 2025, approximately 1.6 million adults across England, Wales, and Scotland utilized these GLP-1 medications for weight loss. Pancreatitis is listed as an "uncommon" side effect in patient information leaflets, affecting about one in 100 individuals.
As of the most recent data, the MHRA's yellow card scheme has logged 1,143 reports of acute and chronic pancreatitis among users of semaglutide and tirzepatide, with 17 reported fatalities. A significant majority of these reports, 973, were logged in 2025. This update emphasizes the importance of patient and healthcare professional awareness of potential symptoms like severe, persistent stomach pain.
In parallel, the MHRA is collaborating on the Yellow Card Biobank study to investigate potential genetic links to pancreatitis risk. This research aims to identify individuals most susceptible to adverse reactions, enabling more personalized prescription strategies. Manufacturers like Novo Nordisk reiterate their commitment to patient safety and recommend strict medical supervision.
